National Academies Press: OpenBook
« Previous: Perspectives
Suggested Citation:"Index." National Research Council. 1987. Drinking Water and Health, Volume 8: Pharmacokinetics in Risk Assessment. Washington, DC: The National Academies Press. doi: 10.17226/1015.
×
Page 477
Suggested Citation:"Index." National Research Council. 1987. Drinking Water and Health, Volume 8: Pharmacokinetics in Risk Assessment. Washington, DC: The National Academies Press. doi: 10.17226/1015.
×
Page 478
Suggested Citation:"Index." National Research Council. 1987. Drinking Water and Health, Volume 8: Pharmacokinetics in Risk Assessment. Washington, DC: The National Academies Press. doi: 10.17226/1015.
×
Page 479
Suggested Citation:"Index." National Research Council. 1987. Drinking Water and Health, Volume 8: Pharmacokinetics in Risk Assessment. Washington, DC: The National Academies Press. doi: 10.17226/1015.
×
Page 480
Suggested Citation:"Index." National Research Council. 1987. Drinking Water and Health, Volume 8: Pharmacokinetics in Risk Assessment. Washington, DC: The National Academies Press. doi: 10.17226/1015.
×
Page 481
Suggested Citation:"Index." National Research Council. 1987. Drinking Water and Health, Volume 8: Pharmacokinetics in Risk Assessment. Washington, DC: The National Academies Press. doi: 10.17226/1015.
×
Page 482
Suggested Citation:"Index." National Research Council. 1987. Drinking Water and Health, Volume 8: Pharmacokinetics in Risk Assessment. Washington, DC: The National Academies Press. doi: 10.17226/1015.
×
Page 483
Suggested Citation:"Index." National Research Council. 1987. Drinking Water and Health, Volume 8: Pharmacokinetics in Risk Assessment. Washington, DC: The National Academies Press. doi: 10.17226/1015.
×
Page 484
Suggested Citation:"Index." National Research Council. 1987. Drinking Water and Health, Volume 8: Pharmacokinetics in Risk Assessment. Washington, DC: The National Academies Press. doi: 10.17226/1015.
×
Page 485
Suggested Citation:"Index." National Research Council. 1987. Drinking Water and Health, Volume 8: Pharmacokinetics in Risk Assessment. Washington, DC: The National Academies Press. doi: 10.17226/1015.
×
Page 486
Suggested Citation:"Index." National Research Council. 1987. Drinking Water and Health, Volume 8: Pharmacokinetics in Risk Assessment. Washington, DC: The National Academies Press. doi: 10.17226/1015.
×
Page 487
Suggested Citation:"Index." National Research Council. 1987. Drinking Water and Health, Volume 8: Pharmacokinetics in Risk Assessment. Washington, DC: The National Academies Press. doi: 10.17226/1015.
×
Page 488

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Index A Absorption extrapolation of, 139- 140 gastrointestinal, 122 rate of, 121 skin, 122-123 ACSL language, 232-233 Adenine arabinoside model, 58 Adenomas, hepatocellular, 459 Administered and delivered doses, 330, 447-455 ADSIM language, 232 Air, excretion into, 142- 143 Allometric equations, 66-67 Allometry, 65-78 valid and invalid extrapolations of, 141 Allyl chloride, 176-179 Alveolar space mass-balance equation, 262 Anatomical models, lower respiratory tract, 305-307 Angiosarcomas, 456-457 Animals no-observable-effect levels (NOELs) for, 4-5 477 pharmacokinetic studies in, 407- 408 polymorphisms in, 146 Anticancer therapy, prospective predictions and validations in, 431- 440 Apparent volume of distribution, 31 Area under tissue curve (AUTC), 11 Areas under concentration-time curves (AUCs), 256, 471-472 Armitage-Doll multistage model, 443 Arterial blood mass-balance equation, 262 AUCs (areas under concentration-time curves), 256, 471-472 AUTC (area under tissue curve), 11 Availability, systemic, 453 Average concentration, 97 Axial dispersion number, 87 B BASIC language, 231-232 Bayesian methods, 190 Bile excretion, 116, 122, 142-143 duct mass-balance equation, 53

478 INDEX Binding affinity, 14 drug, 88-89 plasma, 90 tissue, 90 Bioavailability fraction of dose absorbed and, 122 gastrointestinal absorption and, 122 skin absorption and, 122-123 Birth rate for cells, 380 Blood carboxyhemoglobin, 169 pool mass balance, 46-47 Body clearance, total, 108, 115 mass dependent metric, 70-73 regions, 39-44 size, in pharmacokinetic models, 65-78 weight (BW), 18- 19, 209 Bolus administration, 43 C C language, 231 Cancer model, two-stage, 21 Carbon dioxide mass-balance equation, 263 Carbon monoxide mass-balance equation, 263 Carbon tetrachloride, model for, 312- 324 Carboxyhemoglobin, blood, 169 Carcass mass-balance equation, 262 Carcinogens and carcinogenesis chemical, quantitative risk assessment for, 6 DNA adducts and, 221-226 epigenetic, 16, 20-22 genotoxic, 16 inhibitors of, 222 models of, 443 multistage model of, 463, 467-468 risk assessment, 441-445 Carcinomas, hepatocellular, 371, 459 CCSL IV language, 232 Cell birth versus mutation accumulation, 277 Chronic bioassay, 6 Chronological time, 69, 73 Circulation time, mean, 41 Classical pharmacokinetics, 34-35, 37 Clearance, 17 hepatic, 125- 126 interface between PB-PK models and, 104-107 metabolic, 102 mucociliary, 329 renal, 128-131 total body, 108, 115 value, 81 Closed-chamber kinetics, 170, 172 Cofactor depletion, dose-dependent, 135-137 Compartments choice of, 39-44 deep, 195 linear models of, 104, 105 multicompartments, see Multicompartment model one, see One-compartment model three, see Three-compartment model two, see Two-compartment model Complexes, rates of formation of, 98- 99 Computational equipment needs, 233-234 resources, sharing, 246 Computer languages used in pharmacokinetic model, 230-232 see also specific languages Concentration -dependent metabolite elimination, 134-135 gradient, 27 models, versus experimental, 268- 270 -time curves, areas under (AUCs), 256, 471-472 -time data, 185 Confidence regions, 190- 191 linear, 200, 202

INDEX 479 Contour plots, 200-202 Covalent binding, 11 Critical exposure time, 435 toxicity reference (CTR) system, 354-357, 363-365 Curvilinear dose response, 448-450 Cytochrome P-450 isozymes, 148 Cytosine arabinoside pharmacokinetic model, 57-58 Cytotoxicity -hepatic, 275 modeling of, 273-279 mutation acumulation and, 273-283 D DCM (dichloromethane) (methylene chloride), 171-172, 217-219, 254-264, 392-408, 458-462 De minimus value, 155 Death rate for cells, 380 Dedrick plot, 74-75 Deep compartment, 195 Delivered and administered doses, 330, 447-455 Depletion, 11 cofactor, dose-dependent, 135- 137 glutathione, 175- 177, 178, 179 Detoxification, 452-453 Dibromomethane concentration, 168 Dichloromethane (DCM, methylene chloride), 171-172, 217-219, 254-264, 392-408, 458-462 Diffusion, 28 barriers, 99-102 index, 100 through thick membranes, 122-123 Direct decoupled method, 189 Dispersion number, axial, 87 Distribution intraorgan, extrapolation of, 140- 141 rate constants, 141 - 142 volume of, see Volume of distribution DNA adducts, 221-223 Dose/dosage, 471 administered and delivered, 160, 330, 447-455 dependencies, 120- 139 escalation, 433 extrapolations, 120-125, 170, 172- 173 fraction of, absorbed, 122 -incidence of response curve, 150- 151 log, versus percentage response, 4 low, risks at, 327-328, 444-445 -magnitude of response curve, 150- 151 maximum tolerated (MTD), 6, 432- 433, 449, 450 principle of fraction of, 128-131 response, 3-4, 221, 225-226, 375- 376, 448-450 -route extrapolation, 165- 167, 168, 216-219 safe starting, 433 scaling, 416-419 scheduling, 420-425, surrogates, 293-295 time-dependent, 467-468 time-weighted average, 454 virtually safe (VSD), 296-298 Dosimetry models, 230 comparisons, interspecies, 361-363 hazard assessment using, 353-367 lower respiratory tract mathematical, 357-363 physiologically based, 354-357 Drinking water exposures, modeling, 401-406 Drug binding, 88-89 development, 432-433 disposition, 43 solubility, 89-90 transport, 89-90

480 INDEX E EAI Pacer 500 analog-digital hybrid computer, 335, 336 EDC (ethylene dichloride), 288-300 Efficiency number, 87 Elimination by excretion, 142- 143 half-life of, 30 location of organs of, 116-117 by metabolism, 143-148 organs, 83-86, 109, 112- 114 pulmonary, 385-387 rate constant, 28 species differences in, 142-148 Emphysema, 354 Endogenous precursors, 136 Energetics of muscle, 68-69 Environmental risk assessment, 431 Enzymes idealized distribution of, 127 inhibition, suicide, 173- 175 intraorgan localization of, 126- 128 Epigenetic carcinogens, 16, 20-22 Equilibrium constants, 99 Error analysis in model building, 188- 193 Ethical considerations, 431 Ethylene dichloride (EDC), 288-300 Exact method, l 90 Excess lifetime cancer risks, 6 Excretion biliary, 116, 122 elimination by, 42-143 Exercise, ozone uptake and, 308-310 Experimental error, 191 - 193 Exposure(s) 471 assessment, 8-9 drinking water, modeling, 401-406 intravenous injection, modeling, 406 scenario, extrapolation, 161, 167- 168, 169 time, critical, 435 time-dependent, see Time-dependent exposure Extraction ratio, 82, 85, 105 hepatic, 84 mathematical solution for, 87 Extrapolation, 312, 441-442 in absorption of substances, 139- 140 of allometric methods, 141 dose, 120-125, 170, 172-173 dose-route, 165-167, 168, 216-219 exposure scenario, 161, 167-168, 169 four types of 159 general aspects of, 96-155 from in vitro systems, 80-93 of interorgan distribution of substances, 140-141 interspecies, 212-216, 441-442 low-dose risk, 327-328, 444-445 pharmacokinetic, 161-162 physiologically based models for, 159-180 route-to-route, 114-119 species-to-species, 139- 142, 168- 170, 171, 396-401 F F-Ara-AMP (fludarabine phosphate), 437-438 Fat group (FG) of organs, 447 Feathering process, 29 Fick's First Law, 27, 32-33 Fick's Law of Diffusion, modified, 99-102 First-order rate constants, 90 First-pass elimination organs, 114 nonelimination organs, 113- 114 organs, 109 Flexible polygon method, 189 Flow diagrams, 40, 42 -limited models, 48-49, 446 rate, 32 Fludarabine phosphate (F-Ara-AMP), 437-438 Formaldehyde, 455-456

INDEX 481 linear proportionality and, 328-330 FORTRAN programs, 230-231 Fraction of dose principle, 128-131 Free intrinsic clearance, 82 G Gas-uptake behavior, 175-177 Gastronintestinal absorption, 122 Gavage risk, 375-379 (;enotoxic carcinogens, 16 Glutathione depletion, 175-177, 178, 179 -S-transferase (GST) path, 459-462 Graphic output, 234 GST (glutathione-S-transferase) path, Inhibitors 459-462 Gut mass-balance equations, 53-54, 261 H Half-life, 28, 31 of elimination, 30 minimum, 106 of terminal phase, 106 Half-time to approach maximum concentration, 99 Hazard assessment, 8-9 using dosimetry modeling approach, 353-367 Hepatic clearance, 125- 126 cytotoxicity, 275 extraction ratio, 84 Hepatocellular adenomas, 459 carcinomas, 371, 459 Heteroscedasticity parameter, 193, 195 Humans inhalation, 216, 217 murine toxicity and, 434-435 no-observable-effect levels (NOELs) for, 5 polymorphisms in, 146-147 risk assessment, 369-370 Hybrid rate constants, 106 N-Hydroxy arylamines, urinary bladder exposure to, 334-348 I In vitro systems, extrapolation from, 80-93 Inaccuracy, degree of, 149 Inducers, 144-145 Inhalation model, 165- 167 risk, 375-379 of carcinogenesis, 222 suicide, 137- 139 Initiation index, 224 Intercalating agents, 19-20 Interspecies differences, 153- 155, 330-331 dosimetric comparisons, 361-363 extrapolation, 212-216, 441 -442; see also Extrapolation scaling, 16- 19, 36 . . . ntravenous 1nJectlon exposures, modeling, 406 Intrinsic clearance, 81-82 Isometry, 66 Isozymes, 143-144 cytochrome P-450, 148 interstrain differences in, 145- 146 J Joint risk assessment, 5 Judgmental decisions, 208 K Kidney mass-balance equation, 52, 262 partition coefficients, 91

482 INDEX Kinetic models, see Pharmacokinetic models rate constants, 31 Kleiber equation, 66 Kliment zone model, 307 L Law of Mass Action, 149 Lawrence Solver for Ordinary Differential Equations (LSODE), 190 Lifetime cancer risks, excess, 6 Likelihood estimates, 188- 190 function, 188, 195 ~ . . Llnearlty compartment models, 104, 105 detoxification, 452-453 kinetics, 450 low-dose, 444 proportionality, formaldehyde and, 328-330 steady-state models, 117-118 Lineweaver-Burk plots, 192 Literature evaluation, 15 Liver mass-balance equation, 53, 261 partition coefficients, 91 Low dosage linearity, 444 risk extrapolation, 327-328, 444- 445 versus percentage response, 4 Lower respiratory tract (LRT) anatomical models, 305-307 mathematical dosimetry modeling, 357-363 ozone absorption in, 302-310 Lung administration, 115 dosimetry model, 235 mass-balance equation, 261-262 partition coefficients, 91 M Mammals, flow diagram for, 40 Mass action law, 20 Mass balances, 44 basic, 44, 46-47 blood pool, 46-47 equations for, 14, 51-54, 261-263 simplifications of, 47-56 tissue regions, 47, 48 Mass-specific rates, 73-74 Mathematical pharmacokinetic models, 445-446 Maximum concentration, 97, 99, 112 tolerated dose (MID), 6, 432-433, 449, 450 velocity of reaction, 14 Mean circulation time, 41 Membrane -limited model, 446-447 diffusion through thick, 122-123 permeability, 48-49 resistance, 41 Metabolism clearance, 81, 102 dose-dependent changes in, 125- 139 elimination by, 143-148 interorgan differences in, 145 interspecies differences in, 147-148 pathways, 14 production, 19 rate constants, 212, 288-290 role of, 392-396 sex differences in, 144 strain differences in, 143-144 urinary, 147 Metabolites concentration of, 120 elimination, concentration- dependent, 134- 135 formation and elimination of, 117- 118 functional classification of, 118 reactive nonisolatable, 17, 19

INDEX 483 stable, 17, 18, 119 unstable, 119 Method of residuals, 29 Methotrexate (MIX), 410-425 pharmacokinetic model of, 53-56 Methylchloroform, 392-408 Methylene chloride (dichloromethane, DCM), 171-172, 254-264, 392- 408, 458-462 MFO (mixed-function oxidase) path, 459, 461 M-ice, old, 407-408 Michaelis-Menten kinetics, 81-83, 125-126 Microcomputers, 231-232, 234 Minimum concentration, 97, 112 half-life, 106 Mitotic rate, 380 Mixed-function oxidase (MFO) path, 459, 461 Models adenine arabinoside, 58 Armitage-Doll multistage, 443 anatomical, lower respiratory tract, 305-307 building, 187, 188- 193 cancer, two-stage, 21 carcinogenesis, 443 compartmental, 162 cytotoxicity, 274-277 dosimetry, see under Dosimetry drinking water exposures, 401-406 flow-limited, 446 inhalation, 165- 167 intravenous injection exposures, 406 kinetic, see Pharmacokinetic models Kliment zone, 307 linear compartment, 104, 105 linear steady-state, 117-118 lung dosimetry, 235 mathematical, 445-446 membrane-limited, 446-447 multicompartment, see Multicompartment model multispecies multroute, 391-408 multistage, see Multistage model one-compartment, see One- compartment model parallel tube, 86-87, 113 PB-PK, see Physiologically based pharmacokinetic models PBD, see Physiologically based dosimetry model perfusion-limited physiological, 82- 83 pharmacokinetic, see Pharmacokinetic models physiologically based, see Physiologically based pharmacokinetic models sinusoidal perfusion, 86-87 steady-state, linear, 117- 118 three-compartment, see Three- compartment model two-compartment, see Two- compartment model two-stage carcinogenicity, 21, 273- 274 venous-equilibration, of organ elimination, 83-86 well-stirred, of organ elimination, 83-86, 113 Moolgavkar-Knudson model, 276-277 MTD (maximum tolerated dose), 6, 432-433, 449, 450 MTX, see Methotrexate Mucociliary clearance, 329 Multicompartment model, 29, 235- 239 Multienzyme system, 86 Multispecies multiroute models, 391- 408 Multistage model, 150 of carcinogenesis, 463, 467-468 Murine and human toxicity, comparison of, 434-435 Muscle energetics of, 68-69 group (MG) of organs, 447 mass-balance equation, 51 partition coefficients, 91

484 INDEX Mutation accumulation cell birth versus, 277 cytotoxicity and, 273-283 N National Ambient Air Quality Standards (NAAQs), 353-354 National Biomedical Simulation Resource (NBSR), 233, 246-247 National Toxicology Program (NTP), 449 Nickel injection, 237-239 NOELs (no-observable-effect levels), 4-5 Nonelimination organs, 109- 114 Non-first-pass elimination organs, 109, 112- 113 nonelimination organs, 109- 112 Nonlinear kinetics, 104 method, 190 No-observable-effect levels, see NOELs NTP (National Toxicology Program), 449 o Occupancy, 11 One-compartment model, 28-29, 55 Oral administration, 116 Organs availability, 104 classification of, 108- 110 elimination, 83-86, 109, 112-114 first-pass, 109 grouping of, 447 location of elimination of, 116- 117 nonelimination, see 109- 114 non-first-pass, 109- 113 rapidly equilibrated, 109 slowly equilibrated, 109 Oxidative pathway, saturable, 266 Ozone absorption in lower respiratory tract, 302-310 dosimetry modeling approach with, 353-367 exercise and uptake of, 308-310 uptake of, 360-363 p P (probability), 151 Parallel tube model, 86-87, 113 Parent chemicals, 16- 17 Partition coefficients, 33, 89-90, 91, 288,317,446 Pascal language, 2231, 232 PB-PK models, see Physiologically based pharmacokinetic models PBD (physiologically based dosimetry) model, 354-357 PCE (perchloroethylene), 210-217, 285-290, 369-382, 385-390, 462 Peeling process, 29 Percentage response, log dosage versus, 4 Perchloroethylene (PCE), 210-217, 285-290, 369-382, 385-390, 462 Perfusion-limited physiological model, 82-83 Permeability, membrane, 48-49 Perspectives, 471-475 Pharmacokinetic (PK) models, 13, 36, 162, 229-230, 442 body size in, 65-78 building, 185- 193 classical, 34-35, 37 computer languages used in, 230- 232 conventional approaches to, 234- 235 . . . . data in carcinogenic risk assessment, 441-463 description of, 209-212

INDEX 485 for drinking water exposures, 401- 406 equipment needs for, 233-234 extrapolation, 161-162; see also Extrapolation flow chart of development of, 15 introduction, 27-35 mathematical, 445-446 objective of, 96 physiologically based, see Physiologically based pharmacokinetic models for thiopental, 50-54 uncertaintly in, using SIMUSOLV, 185-207 Physiological time, 69-76 Physiologically based dosimetry (PBD) model, 354-357 Physiologically based pharmacokinetic (PB-PK) models, 13- 14, 36-59, 162-165, 273-274, 442, 446- 447, 472-475 abbreviations and symbols used in specific, 211 for adenosine arabinoside, 58 biological basis of, 38-39 for carbon tetrachloride, 312-324 construction of, 385-390 for cytosine arabinoside, 57-58 description of specific, 209-212 development of, 39, 287-288 diagram of generic, 163 diagram of specific, 210 dose, species, and route extrapolation using, 159- 180 for ethylene dichloride, 288-300 fundamental equation of, 33 general, 96-104 interface between clearance and, 104-107 of intravenous injection exposures, 406 limitations of, 282-283 linear, 107-113 linear compartmentalized, 104, 105 for methotrexate, 53-56, 414-416 Moolgavkar-Knudson, 276-277 multispecies multiroute, 391-408 in old aminals, 407-408 of ozone absorption in lower respiratory tract, 302-310 for percholoroethylene, 285-290, 369-382 physiological and biochemical parameters used in specific, 213 potential of, 35 Ramsey-Andersen, 274-275 risk assessment and, 295-296, 474 route-of-exposure differences and, 298 route-to-route extrapolation of dichloromethane using, 254-264 schematic representation of, 287 sensitivity analysis in, 265-272 simple, 102-103 simplification of, 98 validation of, 283, 317-319 virtually safe doses and, 296-298 Plasma binding, 90 mass-balance equation, 51 membranes, 100 Poly-input availability, 114 Ploymorphisms in animals, 146 in humans, 146-147 Precursors, endogenous, 136 Predictions, prospective, in anticancer therapy, 431-440 Probability (P), 151 Problem identification, 15 Prospective predictions in anticancer therapy, 431-440 Pulmonary fibrosis, 354 uptake and elimination, 385-387 Q Quantitative risk assessment, for chemical carcinogenesis, 6

486 INDEX R R parameter, 103-104 organ/blood, 141-142 Ramsey-Andersen PB-PK model, 274-275 Rapidly equilibrated organs, 109 Rate constants, 99, 106 distributional, 141- 142 hybrid, 106 metabolic, 212 metabolism, 288-190 Rats ingestion by, 214-215 inhalation by, 212-214 old, 407 Reactive nonisolatable metabolites, 17, 19 Reactivity equations, chemical, 11 Receptor binding equations, 11 Reitz-Andersen optimization procedure, 265-272 Renal clearance, 128- 131 Residence time, 139- 140 Residuals, method of, 29 Respiratory tract, see Lower respiratory tract; Upper respiratory tract Response dosage versus, 3-4 percentage, log dosage versus, 4 Risk assessment, 208 at low doses, 327-328, 444-445 carcinogen-DNA adducts in, 221- 226 carcinogenic, 441-463, 443-445 combination techniques, 7 elements of, 9 environmental, 431 extrapolation, low-dose, 327-328 historical perspectives, 3-7 human, 369-370 joint, 5 major elements of, 355 management, major elements of, 355 objective of, 471 PB-PK model and, 295-296, 474 quantitative, see Quantitative risk assessment tissue dosimetry in, 8-23 with time-dependent exposure patterns, 453-455 Route-of-exposure differences, PB-PK model and, 298 Route-to-route extrapolation, 114- 119 S Safe starting dose, 433 Safety factor (SF), 5 Saturable detoxification, 452-453 oxidative pathway, 266 Scaleup, see Extrapolation Scaling interspecies, 16- 19, 36 formulas, 209, 212 SCoP (Simulation Control Program), 232, 233 example program, 239-246 Semipermeable membranes, 100 Sensitivity analysis, 265-272 Sex differences in metabolism, 144 SIMNON language, 232 Simulation, 229 future trends in, 249 general approaches to, 229-230 languages, 232-233 in toxicology, 229-250 training in, 246 Simulation Control Program, see SCoP SIMUSOLV, 185, 186, 233 applications of, 193-205 statistical analysis using, 204 statistical output for, 206-207 uncertainty using, 185-207 Sinusoidal perfusion model, 86-87 Skin absorption, 122- 123 administration, 115

INDEX 487 Slowly equilibrated organs, 109 Solubility of drug, 89-90 Species differences, 38-39 in elimination, 142- 148 Species-to-species extrapolations, 139-142, 168-170, 171, 396- 401 Stable metabolities, 17, 18, 119 Starting dose, safe, 433 Steady statefs) concentration, 107, 118 - conditions, 98-99 distribution ratio, 288 models, linear, 117- 118 term, 107 virtual, see Virtual steady states Suicide enzyme inhibition, 173- 175 inhibitors, 137- 139 Surface area adjustment, 17-19, 160 Systemic availability, 453 T TO (tracheobronchial) liquid lining, 357-361 Terminal half-lives, 106 Thiopental pharmacokinetics model, 50-54 Three-compartment model, 334, 336, 337 Threshold effect, 435-436 Time chronological, 69, 73 integral of tissue exposure, 10 -dependent dosing, 467-468 -dependent exposure, 451-455 physiological, 69-76 -weighted average dose, 454 - weighted average receptor occupancy, 20 , —- ~ssue binding, 90 dosimetry in risk assessment, 8-23 exposure, time integral of, 10 mass balance, 48 partition coefficients, 91 perfusion, 49 regions, 45-47 total concentration, 49-50 volume, 19 Tolerated dose, maximum (MTD), 6, 432-433, 449, 450 Toxicity assessment of, 410-425 comparision of human and murine, 434-435 mechanism of, 412-414 nonsaturable pathway, 266 Toxicology Information Network (TOXIN), 247-248 Toxiphors, 265 Tracheobronchial (TB) liquid lining, 357-361 Transfer constant, 27 Transition rate, 380 Transport, drug, 89-90 Tumor promoters, 21 Tumorigenesis, 5-6 Two-compartment model, 30-31, 32, 43, 194 Two-stage carcinogenicity model, 21, 273-274 TYMNET data communications network, 247 U Unbound concentration, 103, 108 fractions, 88-92, 103 Uncertainty~ies) error analysis and, 188- 193 inherent, 473 using SIMUSOLV, 185-207 Unstable metabolites, 119 Upper respiratory tract (URT), 303 morphology of, 358 Urinary bladder exposure to N-hydroxy arylamines, 334-348 metabolism, 147

488 1 NDEX Urine, excretion into, 142- 143 URT, see Upper respiratory tract V Validations of PB-PK models, 283, 317-319 prospective, in anticancer therapy, 431-440 Variance of error, 191 - 193 VCM (vinyl chloride monomer), 456- 458 Velocity of reaction, minimum, 14 Venous blood mass-balance equation, 262 -equilibration model of organ elimination, 83-86 Vessel-poor group (VPG) of organs, 447 Vessel-rich group (VRG) of organs, 447 Vial equilibration, 164 Vinyl chloride monomer (VCM), 456-458 Virtual steady states, 98-99 validity of assumption of, 105-106 Virtually safe doses (VSD), 296-298 Volume of distribution, 31 VPG (vessel-poor group) of organs, 447 VRG (vessel-rich group) of organs, 447 VSD (virtually safe doses), 296-298 W Well-stirred model of organ elimination, 83-86, 113

Drinking Water and Health, Volume 8: Pharmacokinetics in Risk Assessment Get This Book
×
Buy Paperback | $90.00
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Pharmacokinetics, the study of the movement of chemicals within the body, is a vital tool in assessing the risk of exposure to environmental chemicals. This book—a collection of papers authored by experts in academia, industry, and government—reviews the progress of the risk-assessment process and discusses the role of pharmacokinetic principles in evaluating risk. In addition, the authors discuss software packages used to analyze data and to build models simulating biological phenomena. A summary chapter provides a view of trends in pharmacokinetic modeling and notes some prospective fields of study.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  6. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  7. ×

    View our suggested citation for this chapter.

    « Back Next »
  8. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!